Letter in response to: "Randomised open label exploratory, safety and tolerability study with calmangafodipir in patients treated with the 12-h regimen of N acetylcysteine for paracetamol overdose-the PP100-01 for Overdose of Paracetamol (POP) trial
artículo científico publicado en 2019
Autoría